Skip to main content

Minimum specimen volume requirements for routine coagulation testing: dependence on citrate concentration.

Adcock DM, Kressin DC, Marlar RA

Publication: Am J Clin Pathol (1998) • Vol 109 • Page 595-9PMID: 9576579View on PubMed

Purpose

The purpose of this paper was to determine the effects of tube fill volume and citrate concentration on prothrombin time (PT) and activated partial thromboplastin time (APTT) in plasma from healthy volunteers and patients on anticoagulant therapy.

Conclusion

In general, lower tube fill volumes resulted in increased PT and APTT, reaching statistical significance between fill volumes of 50-80% in healthy volunteers and clinical significance between fill volumes of 60-80% in patients on anticoagulant therapy. The effects of fill volume were slightly greater in tubes containing 3.8% citrate than those containing 3.2% citrate.

Studies (1)

Purpose

The purpose of this study was to determine the effects of tube fill volume and citrate concentration (3.8% versus 3.2%) on PT and APTT in plasma from healthy volunteers and patients on anticoagulant therapy.

Summary of Findings

In plasma from healthy volunteers, PT was significantly increased by tube fill volumes of 70% or less in 3.8% citrate tubes and fill volumes of 50% or less in 3.2% citrate tubes. APTT was significantly increased in plasma from healthy volunteers by fill volumes of 80% or less in 3.8% citrate tubes and fill volumes of 60% or less in 3.2% citrate tubes. Clinically significant increases in PT in specimens from patients on oral anticoagulant therapy were seen with fill volumes of 80% or less in the 3.8% citrate tubes and with fill volumes of 70% or less in the 3.2% citrate tubes. Clinically significant increases in APTT were seen in specimens from patients on oral anticoagulant therapy with fill volumes of 70% or less in the 3.8% citrate tubes and 60% or less in the 3.2% citrate tubes.

  • Biospecimens

    FluidPlasma
    FluidBlood
  • Preservation Types

    None (Fresh)
  • Diagnoses

    Normal
    Not specified
  • Platforms

    MorphologyHematology/ auto analyzer
  • Pre-analytical Factors

    ClassificationPre-Analytical FactorValue(s)
    PreaquisitionOther drugs
    None
    Oral anticoagulant therapy
    Biospecimen AcquisitionAnticoagulant
    Citrate
    Multiple concentrations evaluated
    Biospecimen Aliquots and ComponentsAliquot size/volume
    2.0 mL
    2.5 mL
    3.0 mL
    3.5 mL
    4.0 mL
    4.5 mL
    5.0 mL
    Arbitrarily underfilled (<5.0 mL)